3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
33
Gastrointestinal
15
Breast
13
Gynecologic
12
Thoracic
10
Dermatologic
9
Head & Neck
6
CNS
6
Sarcoma
4
Other hematologic neoplasm
4
NET
2
Lymphoid
2
Endocrine
2
Plasma cell
1
Other
1
Myeloid
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
168
Myelodysplastic Syndromes
160
Leukemia
156
Anemia
151
Leukemia, Myeloid, Acute
144
Neoplasms
124
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Leukemia, Myelomonocytic, Chronic
111
Multiple Myeloma
90
Myeloproliferative Disorders
89
Leukemia, Lymphocytic, Chronic, B-Cell
87
Lymphoma, Non-Hodgkin
76
Hodgkin Disease
71
Lymphoma
66
Congenital Abnormalities
64
Anemia, Refractory
64
Venous Thromboembolism
63
Thrombocytopenia
59
Blast Crisis
57
Leukemia, Myeloid, Chronic-Phase
56
Leukemia, Myeloid, Accelerated Phase
52
Lymphoma, Follicular
51
Myelodysplastic-Myeloproliferative Diseases
48
Anemia, Aplastic
46
Primary Myelofibrosis
44
Lymphoma, Mantle-Cell
44
Neoplasms, Plasma Cell
43
Lymphoma, Large B-Cell, Diffuse
41
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
41
Burkitt Lymphoma
41
Interventions
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urogenital Neoplasms
×
Classical hematology
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled